keyword
MENU ▼
Read by QxMD icon Read
search

Ustekinumab crohn's

keyword
https://www.readbyqxmd.com/read/28026835/ustekinumab-stelara-for-crohn-s-disease
#1
(no author information available yet)
No abstract text is available yet for this article.
January 2, 2017: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/28004853/ustekinumab-therapy-for-crohn-s-disease-during-pregnancy-a-case-report-and-review-of-the-literature
#2
X Cortes, J Borrás-Blasco, B Antequera, S Fernandez-Martinez, E Casterá, S Martin, J R Molés
WHAT IS KNOWN AND OBJECTIVES: The safety of continued ustekinumab (UST) therapy during pregnancy remains unclear in patients with Crohn's disease (CD). There are no meta-analysis reports of exposure to UST during pregnancy. The objective was to describe a case of a pregnant patient with CD who was successfully treated with UST maintenance therapy throughout the pregnancy and delivered a baby boy without any congenital malformations, neurological abnormalities or birth defects. CASE SUMMARY: A 37-year-old patient with CD treated with UST became pregnant...
December 22, 2016: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/27971661/indirect-treatment-comparison-of-ustekinumab-versus-other-biologics-in-moderate-to-severe-crohn-s-disease-a-1-year-treatment-sequence-analysis
#3
M Pacou, L Mesana, A Gauthier, D Naessens, S Sloan, S Danese, S Bonovas, K Abrams
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27965515/ibd-ustekinumab-therapy-for-crohn-s-disease
#4
Iain Dickson
No abstract text is available yet for this article.
January 2017: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27959607/ustekinumab-as-induction-and-maintenance-therapy-for-crohn-s-disease
#5
RANDOMIZED CONTROLLED TRIAL
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao, Omoniyi J Adedokun, Bruce E Sands, Stephen B Hanauer, Severine Vermeire, Stephan Targan, Subrata Ghosh, Willem J de Villiers, Jean-Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce A Salzberg, Pierre Desreumaux, Scott D Lee, Edward V Loftus, Levinus A Dieleman, Seymour Katz, Paul Rutgeerts
Background Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. Methods We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects...
November 17, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27956825/ustekinumab-in-treatment-of-crohn-s-disease-design-development-and-potential-place-in-therapy
#6
REVIEW
Parakkal Deepak, Edward V Loftus
Crohn's disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway has been found to be a major driver of inflammation in adaptive immune responses. Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that blocks the p40 subunit of IL-12 and IL-23 and prevents their interaction with their cell surface receptor and further cytokine activation. It is currently approved in the management of plaque psoriasis and psoriatic arthritis...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27885650/anti-il-12-23p40-antibodies-for-induction-of-remission-in-crohn-s-disease
#7
REVIEW
John K MacDonald, Tran M Nguyen, Reena Khanna, Antje Timmer
BACKGROUND: Ustekinumab (CNTO 1275) and briakinumab (ABT-874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease. OBJECTIVES: The objectives of this review were to assess the efficacy and safety of anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. SEARCH METHODS: We searched the following databases from inception to 12 September 2016: PubMed, MEDLINE, EMBASE, and the Cochrane Library (CENTRAL)...
25, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27722763/ustekinumab-as-effective-treatment-for-refractory-amicrobial-pustulosis-of-the-folds-associated-with-crohn-s-disease
#8
Reem Al-Raddadi, Camille Frances, Philippe Moguelet, Claude Bachmeyer, Sarah Guégan
is missing (Short communication).
October 10, 2016: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/27686963/safety-profile-of-biologic-drugs-in-the-therapy-of-crohn-disease-a-systematic-review-and-network-meta-analysis
#9
Paweł Moćko, Paweł Kawalec, Andrzej Pilc
BACKGROUND: Crohn disease (CD) is an inflammatory bowel disease which occurs especially in developed countries of Western Europe and North America. The aim of the study was to compare the safety profile of biologic drugs in patients with CD. METHODOLOGY: A systematic literature search was performed using PubMed, Embase, and CENTRAL databases, until April 27, 2016. We included randomized controlled trials (RCTs) that compared the safety of biologic drugs (infliximab, adalimumab, vedolizumab, certolizumab pegol, and ustekinumab) with one another or with placebo in patients with CD...
December 2016: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/27450626/ustekinumab-for-the-treatment-of-crohn-s-disease
#10
Tawnya Hansen, Laura E Targownik
INTRODUCTION: Ustekinumab is a human monoclonal antibody directed against the shared p40 subunit of interleukins 12 and 23. Ustekinumab is currently approved for the treatment of psoriatic arthritis (PsA) and moderate to severe plaque psoriasis, and is being evaluated in Crohn's disease (CD). AREAS COVERED: The first evidence supporting the efficacy of ustekinumab in the treatment of moderate to severe CD was published in 2008. Results from subsequent phase II and phase III randomized controlled trials (RCTs) have shown promising data on the clinical efficacy of induction and remission of moderate to severe CD...
September 2016: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27433311/ustekinumab-in-crohn-s-disease-evidence-to-date-and-place-in-therapy
#11
REVIEW
Tal Engel, Uri Kopylov
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending...
July 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27341173/ustekinumab-a-novel-therapeutic-option-in-crohn-s-disease
#12
E G Simon, S Samuel, S Ghosh, G W Moran
INTRODUCTION: Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23. AREAS COVERED: This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world...
August 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27306074/the-next-wave-of-biological-agents-for-the-treatment-of-ibd-evidence-from-cochrane-reviews
#13
Reena Khanna, Nilesh Chande, Séverine Vermeire, William J Sandborn, Claire E Parker, Brian G Feagan
Multiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session...
July 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27306072/ustekinumab-for-the-treatment-of-refractory-crohn-s-disease-the-spanish-experience-in-a-large-multicentre-open-label-cohort
#14
Sam Khorrami, Daniel Ginard, Ignacio Marín-Jiménez, María Chaparro, Mónica Sierra, Mariam Aguas, Beatriz Sicilia, Valle García-Sánchez, Cristina Suarez, Albert Villoria, Carlos Taxonera, Antonio Velasco-Guardado, Javier Martínez-González, Javier P Gisbert
BACKGROUND: Ustekinumab is a fully human monoclonal antibody against IL-12/23. Ustekinumab induced clinical response and maintained higher rate of response than placebo in patients with Crohn's disease (CD). This study aims to assess the effectiveness and safety of ustekinumab in refractory patients with CD in real-life practice. METHODS: Consecutive patients with CD who were treated with subcutaneous ustekinumab between March 2010 and December 2014 were retrospectively included in a multicenter open-label study...
July 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27231440/a-special-meeting-review-edition-ccfa-advances-in-inflammatory-bowel-diseases-2015-highlights-in-ulcerative-colitis-and-crohn-s-disease-a-review-of-selected-presentations-from-the-ccfa-advances-in-inflammatory-bowel-diseases-2015-clinical-and-research-conference
#15
https://www.readbyqxmd.com/read/26958561/ustekinumab-for-successful-treatment-of-refractory-esophageal-crohn-s-disease
#16
Jodie A Barkin, Amar R Deshpande
Esophageal involvement in Crohn's disease is rare. We present a case of refractory esophageal Crohn's disease that responded to ustekinumab, which has shown promise in the treatment of refractory, typically intestinal Crohn's disease. There are no prior reports on the successful use of ustekinumab in esophageal Crohn's disease, but should be considered as a possible management strategy in patients with this condition.
January 2016: ACG Case Reports Journal
https://www.readbyqxmd.com/read/26910458/ustekinumab-in-treatment-of-refractory-paediatric-crohn-disease
#17
LETTER
F L Cameron, V Garrick, R K Russell
No abstract text is available yet for this article.
March 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/26854655/ustekinumab-in-pediatric-crohn-disease-patients
#18
Casey Bishop, Hayley Simon, David Suskind, Dale Lee, Ghassan Wahbeh
OBJECTIVES: We describe the use of ustekinumab for 4 patients with pediatric Crohn disease treated at the Seattle Children's Hospital Inflammatory Bowel Disease Center. METHODS: A retrospective chart review was done to identify patients' clinical data, disease phenotype, treatment history, and laboratory and growth parameters before treatment with ustekinumab and at last follow-up. Adverse events while on ustekinumab were also recorded. RESULTS: Four adolescent patients with Crohn disease at our center received ustekinumab...
September 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/26849718/o-001%C3%A2-a-multicenter-double-blind-placebo-controlled-phase3-study-of-ustekinumab-a-human-il-12-23p40-mab-in-moderate-service-crohn-s-disease-refractory-to-anti-tfn%C3%AE-uniti-1
#19
William Sandborn, Christopher Gasink, Marion Blank, Yinghua Lang, Jewel Johanns, Long-Long Gao, Bruce Sands, Stephen Hanauer, Brian Feagan, Stephan Targan, Subrata Ghosh, Wim de Villiers, Jean-Frédéric Colombel, Scott Lee, Pierre Desreumaux, Edward Loftus, Severine Vermeire, Paul Rutgeerts
BACKGROUND: Interleukins 12&23 are implicated in the pathophysiology of Crohn's disease (CD). These pro-inflammatory cytokines are blocked by ustekinumab (UST). In a previous Phase 2b study (CERTIFI), UST IV induction followed by SC maintenance was shown effective in moderate-severe CD refractory to anti-TNF therapy. This Phase 3 study examined the efficacy and safety of IV UST induction in these patients. METHODS: Patients with moderate-severely active CD (CDAI 220-450) who previously failed or were intolerant to at least 1 TNF-antagonist were randomized (1:1:1) at Week (Wk) 0 to a single dose of IV placebo (PBO), UST 130 mg, or weight-based tiered UST dosing approximating 6 mg/kg (260mg [weight ≤55 kg], 390mg [weight >55 kg and ≤85 kg], 520mg [weight >85 kg])...
March 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/26839964/emerging-issues-in-the-medical-management-of-crohn-s-disease
#20
REVIEW
Laura E Targownik, J Gerard Coneys, Amit S Dhillon
PURPOSE OF REVIEW: This article describes why this review is timely and relevant. The medical management of Crohn's disease is complex, and is changing rapidly with the introduction of novel therapeutic agents and management strategies. RECENT FINDINGS: We have summarized and synthesized up-to-date evidence and opinion on the proper role and composition of combined immunosuppressive therapy in the management of Crohn's disease, the optimal time for introduction of immunomodulator and/or biologic therapies, and the benefits of therapeutic drug monitoring for biologic therapies...
March 2016: Current Opinion in Gastroenterology
keyword
keyword
44834
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"